Alliance Foundation Trials, Llc.

This study tested whether adding the drug palbociclib for two years to standard hormone therapy (taken for at least five years) helps prevent breast cancer from coming back in people with early-stage HR+/HER2- breast cancer. About 5,800 participants with stage II or III cancer to…

This phase II trial tests whether adding the immunotherapy drugs atezolizumab (with or without tiragolumab) to standard chemoradiotherapy can help people with stage III lung cancer that cannot be removed by surgery. About 178 participants will receive the drugs before, during, an…

This study compares active monitoring (regular checkups without immediate treatment) to surgery for people with low-risk ductal carcinoma in situ (DCIS), a very early form of breast cancer. About 1,000 participants are being followed for two years to see if monitoring is as good …

This phase II study tests a combination of two drugs, palbociclib and ibrutinib, in 39 patients with mantle cell lymphoma that has been treated before. The goal is to see if the combo can delay cancer progression. Patients take both pills daily in 28-day cycles.

This phase 3 trial tests whether adding the drug palbociclib to standard anti-HER2 therapy and hormone therapy can help people with HR+/HER2+ metastatic breast cancer live longer without their cancer getting worse. About 518 participants who have already received initial treatmen…

This study tests a combination of four drugs (lenalidomide, ixazomib, dexamethasone, and daratumumab) in 79 adults newly diagnosed with multiple myeloma who cannot have a stem cell transplant. Participants receive the drugs for 12 cycles, then are split into two groups: one conti…